Drug Therapy Protocols: Salbutamol

Policy code	DTP_SAL_0924
Date	September, 2024
Purpose	To ensure a consistent procedural approach to salbutamol administration.
Scope	Applies to all Queensland Ambulance Service (QAS) clinical staff.
Health care setting	Pre-hospital assessment and treatment.
Population	Applies to all ages unless specifically mentioned.
Source of funding	Internal – 100%
Author	Clinical Quality & Patient Safety Unit, QAS
Review date	September, 2026
Information security	UNCLASSIFIED – Queensland Government Information Security Classification Framework.
URL	https://ambulance.qld.gov.au/clinical.html

While the QAS has attempted to contact all copyright owners, this has not always been possible. The QAS would welcome notification from any copyright holder who has been omitted or incorrectly acknowledged.

All feedback and suggestions are welcome. Please forward to: Clinical.Guidelines@ambulance.qld.gov.au

Salbutamol

Drug class

Beta-adrenergic agonist [1,2]

Pharmacology

Salbutamol is a direct acting sympathomimetic agent which mainly affects ß2 – adrenoceptors. It primarily acts as a bronchodilator but also has inotropic and chronotropic actions. Additionally it lowers serum potassium levels through its direct stimulation of the sodium/potassium ATPase pump, drawing potassium into cells.[1,2]

Metabolism

Hepatic with renal excretion.[1]

Indications

- **Bronchospasm**
- **Suspected hyperkalaemia** (with QRS widening AND/OR AV dissociation)

Contraindications

- Allergy AND/OR Adverse Drug Reaction
- Patients less than 1 year of age

Precautions

- Acute pulmonary oedema
- Ischaemic heart disease

Side effects

- Anxiety
- Tachyarrhythmias
- Tremors
- Hypokalaemia and metabolic acidosis

Presentation

- Metered Dose Inhaler, 100 microg/puff *salbutamol*
- Nebule, 2.5 mg/2.5 mL *salbutamol*
- Nebule, 5 mg/2.5 mL *salbutamol*
- Ampoule, 500 mcg/1 mL *salbutamol*

Onset	Duration	Half-life
2–5 minutes	16–60 minutes	1.6 hours

Schedule

- Metered dose inhaler, S3 (Therapeutic Poison).
- NEB, S4 (Restricted drugs).

Routes of administration

Metered Dose Inhaler (MDI)	FR C AT P ACP1 ACP2 CCP
Nebuliser (NEB)	FR C AT P ACP1 ACP2 CCP
Intravenous infusion (IV INF)	CCP

Special notes [1–6]

- Ambulance officers must only administer medications for the listed indications and dosing range. Any consideration for treatment outside the listed scope of practice requires mandatory approval via the *QAS Clinical Consultation and Advice Line*.
- Salbutamol Metered Dose Inhalers (MDIs) are the preferred formulation for the management of bronchospasm. Use of the MDI (compared to nebuliser) reduces aerosolisation (and exposure to respiratory viruses) and reduces the incidence of salbutamol side effects. Where clinically appropriate, salbutamol should be administered using a MDI in preference to a nebuliser.
- Different preparations of salbutamol are used for nebulised and IV routes. The inappropriate IV administration of nebuliser salbutamol solution will cause serious adverse effects.
- For patients with COPD, nebulised salbutamol must be delivered via nebuliser mask at a rate of 6 L/minute. For all other patients 8 L/minute is appropriate.
- Nebulised salbutamol will reduce serum potassium by 0.5–1 mmol/L within 30 minutes.
- The manufacturer recommends that nebules must be stored within the foil packet and must be discarded three months after opening. The date that the foil packet is opened should then be clearly marked on the packet.
- All salbutamol infusions must be initiated using hospital supplies. The intravenous presentation of salbutamol will not be carried by QAS.
- Salbutamol MDIs are single patient use only.

Salbutamol

Adult dosages [1–6]

Bronchospasm

FR	MDI	**12 (1.2 mg) MDI inhalations** **Single dose only.**
AT **C** **P** **ACP1** **ACP2** **CCP**	MDI	**12 (1.2 mg) MDI inhalations** Repeat at **10 minutes.** **No maximum dose.**
FR	NEB	**5 mg** **Single dose only.**
AT **C** **P** **ACP1** **ACP2** **CCP**	NEB	**5 mg** Repeated PRN. **No maximum dose.**
E CCP	IV INF	RSQ Clinical Coordinator consultation and approval required in all situations. Commence infusion at 5 microg/minute (5 mL/hour) and increase by 2.5 microg/minute (2.5 mL/hour) every 3–5 minutes as determined by patients respiratory status.

Suspected hyperkalaemia
(with QRS widening AND/OR AV dissociation)

CCP	NEB	**20 mg** **Single dose only.**

Paediatric dosages [1–6]

Bronchospasm

FR	MDI	1–5 years – **6 (600 microg) MDI inhalations** **Single dose only.** ≥ 6 years – **12 (1.2 mg) MDI inhalations** **Single dose only.**
AT **C** **P** **ACP1** **ACP2** **CCP**	MDI	1–5 years – **6 (600 microg) MDI inhalations** Repeated at 10 minutes. **No maximum dose.** ≥ 6 years – **12 (1.2 mg) MDI inhalations** Repeated at 10 minutes. **No maximum dose.**
FR	NEB	1–5 years – **2.5 mg** **Single dose only.** ≥ 6 years – **5 mg** **Single dose only.**
AT **C** **P** **ACP1** **ACP2** **CCP**	NEB	1–5 years – **2.5 mg** Repeated PRN. **No maximum dose.** ≥ 6 years – **5 mg** Repeated PRN. **No maximum dose.**

Suspected hyperkalaemia
(with QRS widening AND/OR AV dissociation)

CCP	NEB	**5 mg** **Single dose only.**